Harvard Bioscience
HBIO
62 hedge funds and large institutions have $55.8M invested in Harvard Bioscience in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 26 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.09% less ownership
Funds ownership: 6.3% → 6.2% (-0.09%)
9% less funds holding
Funds holding: 68 → 62 (-6)
16% less capital invested
Capital invested by funds: $66M → $55.8M (-$10.3M)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
31% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.59M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$1.33M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$420K |
| 4 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$303K |
| 5 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$288K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$1.5M |
| 2 |
FM
Fondren Management
Houston,
Texas
|
-$702K |
| 3 |
2L
22NW LP
Seattle,
Washington
|
-$581K |
| 4 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$204K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$174K |
HBIO Hedge Fund Activity: Q1 2017 in Review
62 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q1 2017, worth a combined $55.8M — down 16% from $66M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of HBIO and 5 opened new positions — a net loss of 1 holder — while 26 trimmed existing stakes and 18 added.
The largest buyer was BlackRock, opening a new position worth an estimated $4.59M. The largest seller was Granahan Investment Management, cutting an estimated $1.5M.
- 62 institutional investors held Harvard Bioscience (HBIO) as of Q1 2017, down from 68 in Q4 2016.
- Funds reported $55.8M of Harvard Bioscience stock for Q1 2017, down 16% quarter-over-quarter.
- 5 funds opened new Harvard Bioscience positions in Q1 2017 and 6 closed out, a net change of -1 holder.
- The largest Harvard Bioscience buyer in Q1 2017 was BlackRock, an estimated $4.59M added.
- The largest Harvard Bioscience seller in Q1 2017 was Granahan Investment Management, an estimated $1.5M sold.
Based on aggregated 13F filings for Q1 2017.